Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine

Neurology

Volumn 78, Issue 13, 2012, Pages 976-984

  Silberstein, S D ^a   Dodick, D W ^b   Lindblad, A S ^c   Holroyd, K ^d   Harrington, M ^c   Mathew, N T ^e   Hirtz, D ^f  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b MAYO CLINIC   (United States)

^c EMMES CORPORATION   (United States)

^d OHIO UNIVERSITY   (United States)

^e Houston Headache Clinic   (United States)

^f NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; PROPRANOLOL; TOPIRAMATE;

ABNORMAL DREAMING; ADD ON THERAPY; ADULT; AGED; AMNESIA; ANXIETY; APHASIA; ARTICLE; BECK DEPRESSION INVENTORY; COLD LIMB; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FATIGUE; FEMALE; HUMAN; HYPOTENSION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MIGRAINE DISABILITY ASSESSMENT; MIGRAINE SPECIFIC QUALITY OF LIFE; MONOTHERAPY; MORNING DOSAGE; PARESTHESIA; POLYPHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; TRANSFORMED MIGRAINE; TREATMENT OUTCOME;

EID: 84860787394     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31824d5846     Document Type: Article

References (20)

1. Dodick D. Clinical practice: Chronic daily headache. N Engl J Med 2006;354:158-165. (Pubitemid 43076713)
2. Friedank-Mueschenborn E, Fox AW. Cusums to measure chronic daily headache. Headache 2006;46:110-114.
3. Stovener LJ, Hagen K, Jensen R, et al. The global burden of headache: A documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210. (Pubitemid 46354128)
4. Coeytaux RR, Linville JC. Chronic daily headache in a primary care population: Prevalence and headache impact test scores. Headache 2007;47:7-12. (Pubitemid 46096051)
5. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26:742-746.
6. Diener HC, Bussone G, Van Oene JC, Lahaye M, Schwalen S, Goadsby PJ, for the TOPMAT-MIG-201 (TOP-CHROME) Study Group. Topiramate reduces headache days in chronic migraine: A randomized, doubleblind, placebo-controlled study. Cephalalgia 2007;27: 814-823. (Pubitemid 46961730)
7. Silberstein SD, Lipton RB, Dodick DW, et al, Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: A randomized, double-blind, placebo-controlled study. Headache 2007;47:170-180.
8. Silvestrini M, Bartolini M, Coccia M, Baruffaldi R, Taffi R, Provinciali L. Topiramate in the treatment of chronic migraine. Cephalalgia 2003;23:820-824. (Pubitemid 37255424)
9. Silberstein SD. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55: 754-762.
10. Pascual J, Rivas MT, Leira R. Testing the combination beta-blocker plus topiramate in refractory migraine. Acta Neurol Scand 2007;115:81-83. (Pubitemid 46018541)
11. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979;35:549-556. (Pubitemid 10242750)
12. Freidlin BF, Korn EL, Gray R. A general inefficacy monitoring rule for randomized clinical trials. Clinical Trials 2010;7:197-208.
13. Silberstein S, Tfelt-Hansen P, Dodick D, et al, for the Task Force of the International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults. Cephalalgia 2008;28:484-495. (Pubitemid 351502554)
14. Bartolini M, Silvestrini M, Taffi R, et al. Efficacy of topiramate and valproate in chronic migraine. Clin Neuropharmacol 2005;28:277-279. (Pubitemid 44378618)
15. Rothrock JF, Parada VA, Drinkard R, Zweifler RM, Key KF. Predictors of a negative response to topiramate therapy in patients with chronic migraine. Headache 2005;45:932-935. (Pubitemid 41045372)
16. Diener HC, Dodick DW, Aurora SK, et al, PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the doubleblind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804-814.
17. Aurora SK, Dodick DW, Turkel CC, et al, PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Results from the doubleblind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803.
18. Dodick DW, Turkel CC, DeGryse RE, et al, PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: Pooled results from the double-blind, randomized, placebocontrolled phases of the PREEMPT clinical program. Headache 2010;50:921-936.
19. Ko DT, Herbert PR, Coffey CS, Sedrakyan A, Curtis JP, Krumholz HM. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288:351-357. (Pubitemid 34761614)
20. Ashtari F, Shaygannejad V, Akbari M. A double-blind, randomized trial of low-dose topiramate vs propranolol in migraine prophylaxis. Acta Neurol Scand 2008;118: 301-305.